Search

Displaying results 551 - 560 of 4626 in total
  1. Drug

    Lefamulin

    go.drugbank.com/drugs/DB12825
    Approved

    Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is av...

  2. Drug

    Ergoloid mesylate

    go.drugbank.com/drugs/DB01049
    Approved

    [A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA.

  3. Drug

    Prazosin

    go.drugbank.com/drugs/DB00457
    ApprovedInvestigational

    Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists.

  4. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis...

  5. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. … [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.

  6. Drug

    Cefoperazone

    go.drugbank.com/drugs/DB01329
    ApprovedInvestigationalWithdrawn

    It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis

  7. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

  8. Drug

    Palivizumab

    go.drugbank.com/drugs/DB00110
    ApprovedInvestigational

    Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). … Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)

  9. Drug

    Albutrepenonacog alfa

    go.drugbank.com/drugs/DB13884
    Approved

    [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.

  10. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    [A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. … [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794]